The immune response against cancer is mediated by a group of cells, known as cytotoxic cells that recognize and eliminate the mutated cells in cancer. However, cancer cells have several mechanisms to evade this immune response that threaten their survival, such as controlling the cytotoxic anti-tumor cells using molecules named “Immune Checkpoints”, that inhibit immune cells and allow the malignant cells to escape and proliferate, leading to tumors. The pharmacological control of these molecules in gastric cancer could be one of the most successful alternatives to classical cancer therapies, giving rise to better survival of this patients.
Speaker: Ignacio Juárez, PhD candidate at the Department of Immunology at School of Medicine in Complutense University (UCM); Fellow at the Department of Rheumatology, Beth Israel Deaconess Medical Center at Harvard Medical School.
Sponsors: RCC; Rheumatology Department Lab Meeting, Beth Israel Deaconess Medical Center (BIDMC) at Harvard Medical School.
LOCATION:Immunotherapy potential in Gastric Cancer: Lymphocyte infiltration and PD1/PDL1 pathway STATUS:CONFIRMED DTSTART:20190913T130000Z DTEND:20190913T140000Z END:VEVENT END:VCALENDAR